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Introduction
Indocyanine Green (ICG) is a compound that was developed in the 
1950s by Kodak. It was meant to be employed in the photography. In 
1956 its use via intravenous injection was approved in the medical field. 
Since then, it has mainly been employed in ophthalmology where it is 
used for Fluor angiographies. Since a few years, ICG has successfully 
been employed in Sentinel Lymph Node (SLN) mapping [1]. After an 
off label interstitial injection of the tracer, a fluorescent signal can be 
elicited with a dedicated device that emits light in the Near Infrared 
(NIR) wavelength. This allows for an easy identification of the SLN. In 
gynecologic oncology this tracer has proven to be at least equivalent 
to the combination of technetium-99m Tc-99m and blue dyes as far as 
detection rates goes [2-6]. ICG seems to perform better in obese patients 
and is user friendlier as it does not require a preoperative intracervical 
injection as is the case with Tc-99m. This ease of use is perceived by 
the patients as a better quality of delivered care [7]. Furthermore, its 
toxicity profile seems to compare well with that of the other tracers 
that are commonly employed for SLN mapping [8]. The information 
on the toxicity profile of the ICG mainly relates to the ophthalmologic 
literature, where this compound has been employed for a long interval 
of time. ICG is considered to be a safe drug with an estimated rate of 
allergic reactions of 0.05% [9].
Case report
We report a case of a 65-year-old woman affected by a 
carcinosarcoma that was clinically and radiologically confined to 
the uterus who underwent an anaphylactic reaction to ICG. The 
patient was planned to undergo a laparoscopic hysterectomy, 
bilateral salpingo-oophorectomy, SLN biopsy followed by a pelvic 
and paraaortic lymphadenectomy. After a general anesthesia was 
obtained, a laparoscopy was performed. After having obtained a 
pneumoperitoneum, having inserted the optic trocar and three 
ancillary trocars and having explored the abdominal organs to rule out 
extrauterine spread of the disease, 8 ml of an ICG solution (5 mg/ml) 
were injected interstitially in the cervix as previously described [1]. The 
solution of ICG was obtained through the suspension of one vial of 25 
mg ICG powder (Pulsion) with 5 ml of sterile water. Approximately 
one minute after ICG injection, the patient collapsed secondary to an 
anaphylaxis and had to be resuscitated with CPR, 2.2 mg adrenalin, 2 
mg Tavgyl and 125 mg Solu-Medrol. Eventually, the cardiovascular 
system recovered, and the patient was transferred to the ICU. The 
patient recovered completely without any signs of neurological damage. 
The patient had a slight reaction to ICG in the prick test. Esmeron, 
fentanyl, propofol, latex and chlorhexidine all tested negative. After 
having recovered, allergic test were performed to identify the agent that 
was responsible for the anaphylaxis. Based on these results and on the 
timing of the allergic reaction ICG was considered to be responsible for 
the allergic reaction. The patient war re-operated on ten days later. A 
laparoscopy with total hysterectomy, bilateral salpingo-oophorectomy, 
pelvic and paraaortic lymphadenecomy was performed without 
complications. 
Discussion
In our cohort of 234 patients (58 cervical cancer patients and 176 
endometrial cancer patients) who have been subjected to interstitial 
injection of ICG for SLN mapping since 2013 this is the only case of 
allergic reaction that we have recorded, accounting for an incidence of 
severe allergic reactions of 0.4%. No other adverse effects of any grade 
have been recorded in our cohort of patients. In the past few years 
several series on patients undergoing ICG SLN mapping for various 
oncologic diagnoses have been published and no severe reactions have 
been reported so far. Although there is a tendency to underreport 
negative results and complications in the literature, it is plausible that 
the real incidence of an anaphylactic reaction to ICG is lower that what 
we have recorded. Still, severe allergic reaction is much more common 
to blue dyes as compared to ICG with a reported rate that varies 
between 0.7% and 1.9% [10-14].
Our patient was injected with a relatively high dose of ICG. 
Different centers have been using different doses and concentrations of 
ICG for SLN mapping which are typically lower than the one adopted 
at our institution, ranging from 0,5 to 2,5 mg/ml [2,15]. It is unlikely 
that the higher dose of ICG injected is responsible for the recorded 
allergic reaction.
An anaphylactic shock is a dramatic life-threatening event that can 
occur with virtually any medication. Depending on the mechanism of 
action, allergic reactions are divided into four types:
• Type I: IgE mediated. This type of allergic reaction is characterized 
by a rapid response that occurs in minutes. Free antigens cross 
link the IgE on mast cells and basophils causing a release of 
vasoactive biomolecules. This type of reaction can be responsible 
for anaphylactic reactions.
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• Type II: IgM or IgG mediated. Ig G or Ig M antibodies bind to cell 
surface antigens, with subsequent complement fixation. This type of 
reaction is responsible for, among others, autoimmune hemolytic 
anemia.
• Type III: IgG mediated. Circulating antigen-antibody immune 
complexes deposit in postcapillary venules, with subsequent 
complement fixation. This type of reaction is responsible for the 
lupus erythematosus systemic.
• Type IV: T-cell mediated. Helper T cells are activated by an antigen 
presenting cell. At the subsequent exposure, the memory T helper 
cells will activate macrophages and cause an inflammatory response. 
This type of reaction is responsible, among others, for contact 
dermatitis.
Based on their severity allergic reactions are classified in three 
grades: 
• Grade 1: urticaria or blue hives, Pruritus, and/or a generalized rash;
• Grade 2: transient hypotension (systolic blood pressure ≥ 70 mm 
Hg) not requiring vasopressors;
• Grade 3: hypotension (systolic blood pressure < 70 mm Hg) 
requiring vasopressor support. Grade 3 reactions are life threatening 
and typically require an ICU admission.
ICG contains sodium iodide and, according to the manufacturer, 
it should be used with caution in patients who have a history of 
allergy to iodides because of the risk of anaphylaxis. Since iodine is a 
chemical element that is an essential component of the human body, 
some authors suggest that ICG can be safely employed in patients 
with iodine allergy since a type-I allergic reaction (antibody mediated, 
responsible for anaphylactic shock) can virtually not occur [16]. Still, 
type I reactions may occur to other excipients of ICG.
It is crucial to be aware of the potential allergic reactions that may 
occur after the administration of ICG and the anesthesiologist should 
always be notified when ICG is injected. Overall ICG remains a very safe 
product that performs better than the other conventional tracers (such 
as Tc-99m and blue dyes alone or in combination) when adopted for 
the SLN mapping in gynecologic oncology [2-6,8]. Although adverse 
reactions resulting from an intravenous or an interstitial injection of 
ICG are expected to be the same, since ICG has only been approved 
by FDA for intravenous injection, it is crucial to inform the patients 
undergoing SLN mapping on its off-label use as adverse reactions may 
otherwise lead to unpleasant medico-legal consequences.
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